Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher, Jutta Auberger, Johannes Clausen, Brigitte Kircher Biology of Blood and Marrow Transplantation Volume 13, Issue 8, Pages 942-947 (August 2007) DOI: 10.1016/j.bbmt.2007.04.007 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Mean VEGF and activin-A serum levels ± SE following allogeneic hematopoietic SCT. Biology of Blood and Marrow Transplantation 2007 13, 942-947DOI: (10.1016/j.bbmt.2007.04.007) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Correlation between VEGF serum levels on day +15 and a, maximal total serum bilirubin and b, number of days with total serum bilirubin ≥ 2 mg/dL within the first 20 days following allogeneic hematopoietic SCT. Biology of Blood and Marrow Transplantation 2007 13, 942-947DOI: (10.1016/j.bbmt.2007.04.007) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Overall survival of patients with high versus low VEGF serum levels on day +15 following allogeneic hematopoietic SCT. The median value of VEGF (151 pg/mL) on day +15 was used to discriminate between patients with high and low VEGF levels. Biology of Blood and Marrow Transplantation 2007 13, 942-947DOI: (10.1016/j.bbmt.2007.04.007) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions